CD4 and tuberculosis: Cohort(s): randomized double-blind Phase II trial of HIV-infected adults from Tanzania; CD4 counts >350, ARV naïve, no TB diseaseImmunization: H1 in IC31 i.m. (+0, +56 days; n = 20)Buffer i.m. (+0, +56 days; n = 4)